Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss
Huvudupphovsmän: | Schmidt, W, Gough, S, Madsbad, S, Zinman, B, Falahati, A, Toft, A, Sesti, G |
---|---|
Materialtyp: | Conference item |
Publicerad: |
2009
|
Liknande verk
Liknande verk
-
Liraglutide Is Associated with Reduced Rates of Hypoglycemic Events Versus Glimepiride When Achieving Target HbA(1c)
av: Gough, S, et al.
Publicerad: (2010) -
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.
av: Zinman, B, et al.
Publicerad: (2012) -
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
av: Zinman, B, et al.
Publicerad: (2012) -
Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes
av: Matthews, DR, et al.
Publicerad: (2008) -
The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide.
av: Jing Lv, et al.
Publicerad: (2014-01-01)